Elanco Animal Health Incorporated $ELAN Shares Sold by ASR Vermogensbeheer N.V.

ASR Vermogensbeheer N.V. decreased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 18.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,610,193 shares of the company’s stock after selling 353,591 shares during the quarter. ASR Vermogensbeheer N.V.’s holdings in Elanco Animal Health were worth $32,431,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Hsbc Holdings PLC boosted its holdings in shares of Elanco Animal Health by 434.2% in the second quarter. Hsbc Holdings PLC now owns 126,334 shares of the company’s stock valued at $1,801,000 after acquiring an additional 102,686 shares in the last quarter. Norges Bank purchased a new position in Elanco Animal Health during the 2nd quarter worth approximately $12,502,000. Yousif Capital Management LLC boosted its position in Elanco Animal Health by 1,333.7% during the 3rd quarter. Yousif Capital Management LLC now owns 168,133 shares of the company’s stock worth $3,386,000 after acquiring an additional 156,406 shares during the period. Equitable Trust Co. increased its stake in Elanco Animal Health by 65.5% in the 2nd quarter. Equitable Trust Co. now owns 248,108 shares of the company’s stock valued at $3,543,000 after buying an additional 98,172 shares during the period. Finally, First Horizon Advisors Inc. grew its stake in Elanco Animal Health by 184.3% in the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after purchasing an additional 2,414 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insider Activity at Elanco Animal Health

In other news, insider Rajeev A. Modi acquired 4,500 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the transaction, the insider directly owned 123,082 shares in the company, valued at $2,625,339.06. This trade represents a 3.79% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Robert M. Vanhimbergen acquired 6,950 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the completion of the acquisition, the chief financial officer directly owned 124,233 shares of the company’s stock, valued at $2,688,402.12. This trade represents a 5.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 43,450 shares of company stock worth $937,883 in the last 90 days. Corporate insiders own 0.89% of the company’s stock.

Elanco Animal Health Stock Up 1.5%

Shares of NYSE ELAN opened at $24.54 on Friday. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $24.84. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The business has a fifty day moving average of $22.50 and a two-hundred day moving average of $19.63. The stock has a market cap of $12.19 billion, a PE ratio of 409.07, a PEG ratio of 3.36 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter last year, the company posted $0.13 EPS. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ELAN. JPMorgan Chase & Co. raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. Barclays began coverage on Elanco Animal Health in a research note on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price target on the stock. Morgan Stanley raised their price objective on Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, December 18th. Finally, Stifel Nicolaus boosted their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.78.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.